Raymond James & Associates Infla Rx N.V. Call Options Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
Call Options
3 transactions
Others Institutions Holding IFRX
# of Institutions
35Shares Held
13.2MCall Options Held
5.2KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$8.77 Million0.42% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$3.17 Million0.33% of portfolio
-
Eversept Partners, LP New York, NY1.57MShares$2.4 Million0.21% of portfolio
-
Morgan Stanley New York, NY828KShares$1.27 Million0.0% of portfolio
-
Ubs Oconnor LLC Chicago, IL722KShares$1.1 Million0.07% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $67.6M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...